Quanterix Corporation (QTRX) Stock Analysis & Winston Score

Quanterix Corporation makes ultra-sensitive blood testing technology used to detect tiny amounts of proteins in the body. Its main product is the Simoa (Single Molecule Array) platform — a specialized analyzer and related test kits that can measure biological markers at concentrations far lower than standard lab equipment. The company primarily sells to research labs, pharmaceutical companies, and academic institutions studying diseases like Alzheimer's, traumatic brain injury, and other neurological conditions. Quanterix earns revenue by selling its Simoa instruments to labs and then generating recurring income from consumables and reagent kits those labs need to run tests. The company operates mainly in the United States and Europe and is relatively small, with a market cap around $200 million. Its deep sensitivity advantage in protein detection gives it a niche position, but the company is spending far more than it earns, posting an operating margin of roughly negative 83%, meaning its biggest risk is burning through cash before its technology reaches broader clinical or commercial adoption.